Risk of Sudden Death Declining in Heart Failure Patients

Share this content:
Risk of Sudden Death Declining in Heart Failure Patients
Risk of Sudden Death Declining in Heart Failure Patients

THURSDAY, July 6, 2017 (HealthDay News) -- Rates of sudden death from heart failure have declined by nearly half over the past two decades, according to research published in the July 6 issue of the New England Journal of Medicine.

John McMurray, M.D., a professor of cardiology with the University of Glasgow in the United Kingdom, and colleagues analyzed data on 40,195 heart failure patients enrolled in 12 clinical trials conducted between 1995 and 2014.

The combined data from the clinical trials showed that sudden death rates have fallen by 44 percent in heart failure patients who have not received an implantable cardioverter-defibrillator (ICD). The researchers also found that the rate of sudden death was not higher among newly diagnosed heart failure patients.

"Our findings add to the recent debate about who should get an ICD given that these are expensive devices, the implantation of which can be associated with complications," McMurray told HealthDay. "The majority of patients receiving an ICD never use it. So, while everyone agrees that ICDs are a valuable and lifesaving treatment, we haven't yet worked out who most needs and benefits from an ICD -- i.e., how to target ICDs to the highest-risk patients."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths